Outlook Therapeutics, Inc.
OTLK
$0.50
-$0.01-1.37%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 34.04% | 56.53% | -366.76% | 205.34% | -87.18% |
| Total Depreciation and Amortization | 1.02% | 1.03% | 1.04% | 0.00% | 0.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -139.35% | -83.08% | 201.15% | -30.98% | 56.70% |
| Change in Net Operating Assets | 49.25% | 136.90% | -185.97% | 63.21% | 337.25% |
| Cash from Operations | -4.00% | 28.24% | -51.21% | 35.42% | 12.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -156.41% | 97.24% | -- | -- | -- |
| Issuance of Common Stock | -1.89% | -22.44% | 947.26% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -12.73% | -28.16% | 958.17% | 1,615.13% | -102.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.82% | -27.47% | 120.09% | 46.04% | -12.44% |